

Humber Area Prescribing Committee

Date / Time	5 th October 2022 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	Yes

Attendance	Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Andrew Karvot – Advanced Clinical and Northern Lincolnshire - Interface Pharmacist (AK) Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Catherine Mannion- Medicines Optimisation Pharmacist, NECS (CM) Emma Baggaley, Head of Medicines Service, CHCP (EB) Dr Narayana Pothina- Consultant in adult medicine – NLAG (NP) Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS) Simon Priestley- Chief Pharmacist, NLAG (SP) Marian Opoku-Fofie – Deputy Chief Pharmacist – Humber Teaching NHS Foundation Trust (MOF) Prof A Morice – Professor of Respiratory Medicine, Chair of D&TC HUTH (AM) Dr Rolan Schreiber, Professional Secretary LMC (RSx) Simon Gaines- Deputy Chief Pharmacist- HUTH (SG) – Attending on behalf of JG Daniel Newsome- RDTC (DN)
-------------------	--

Apologies	Joanne Goode – Chief Pharmacist – HUTH (JG)
------------------	---

Agenda Number	Item	Discussion	Action	Lead	Due Date
2022.10.01	Apologies	Noted above			
2022.10.02	Declarations of interest	None			
2022.10.03	Minutes of previous meeting	Accepted as true record			
2022.10.04	Action Tracker	<ul style="list-style-type: none"> • Outstanding actions from NLAPC-Overactive bladder pathway – JM to contact Mr Gandhi with pathway for agreement in HUTH and to contact ICP team to see if discussed there.- JM received no correspondence from Mr Gandhi, will contact again and contact urology • Guidelines-Update headache guidance and upload on website- JM updated and AK uploaded • Joint formulary Transfer chapter 4 onto netformulary site- JM has transfer up to 4.8 with process ongoing • Ratification of guidelines and SCFs Upload approved guidelines to Humber APC website- Uploaded • Prescription requests in primary care –action transferred from NLAPC to Humber APC To produce joint document detailing supply details from secondary to primary care for all providers within Humber region To add links to relevant HUTH and NLAG guidance to website for information for primary care (discharge policies) • Ratification of guidelines and SCFs- Add type 2 diabetes guidelines as recommendation for discussion at IMOC (action complete) NEW actions To feedback IMOC recommendation to clinicians To feedback to APC when meeting between all services occurred- NP met with clinicians and discussed guidelines. JM to contact Matthew Heppel for feedback 	<p>JM to contact Mr Gandii and Urology Update next meeting</p> <p>Action complete</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Ongoing</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM/AK</p> <p>JM</p>	<p>11/22</p> <p>9/22</p> <p>11/22</p> <p>9/22</p> <p>9/22</p> <p>11/22</p>

		<p>RS and KMC raised concerns with GLP1, it was discussed within the group. Consensus was to use current guidelines and await outcome as it is close to NICE as possible.</p> <ul style="list-style-type: none"> • Traffic Light Status Update formularies and red list • Ratification of guidelines and SCFs Add agenda items not covered onto next agenda • AOB To add classifications into net formulary for vitamin K (Green for Phytomenadione and Amber 1 for menadiol) • AOB To update meetings to have APC monthly for next 3 months and review in January. To alternate joint formulary and guideline group. 	Action complete	JM/AK	10/22
			Action complete	JM	10/22
			Action complete	JM	10/22
			Action complete	JM/LS	10/22
2022.10.05	Outstanding actions from NLAPC	<ul style="list-style-type: none"> • Mycophenolate- Awaiting funding • <i>Modafinil</i>- Shared care approved, awaiting confirmation of funding in both NEL/NL as want to launch when funding available at both Places • <i>Azathioprine shared care for gastro</i>- Shared cared accepted, awaiting clarification around funding. • <i>Riluzole shared care</i>- Shared care approved, awaiting confirmation of funding in both NEL/NL as want to launch when funding available at both Places • ADHD Shared care (NL) – awaiting confirmation of funding- Going to mental health meeting update next meeting • <i>Prescribing in gestational diabetes</i>- Discussed at business meeting and currently being looked at standardisation of practice across Northern Lincolnshire places- update next meeting • <i>Appropriate prescribing of specialist infant formulae</i>- AK has emailed a community dietitian to ask if they are happy to review and work with north bank on this- AK not received back, update next meeting • 6-monthly triptorelin therapy (Decapeptyl SR 22.5mg) - CSU to prepare information regarding potential cost savings for switch to long term 6 monthly triptorelin with initial 28-day preparation.- Discussion of cost 	Ongoing Ongoing		
			Ongoing		
			Ongoing		
			Ongoing		
			Ongoing		
			Ongoing		
			Ongoing		
			Action complete New action for HAPC -		10/22

		affect and approved. JM/AK to circulate HERPC guidance for prostate cancer therapy to urologists in NLAG for discussion of adaption of guidance.			
2022.10.06	Outstanding actions from HERPC	<ul style="list-style-type: none"> • Correspondence Received Rheumatology to prepare pathway with rituximab without MTX August update – JM to contact Dr Ogumbambi for timeline No contact from Dr Ogumbambi, JM to chase • Feedback From Commissioning Groups KMc and JM to work with CCG to approve MS guideline August update – JM to contact Gary Hepworth September update – JM updated document and sent to Gary Hepworth • Hydroxychloroquine SCF JM to discuss ophthalmology checks with rheumatology New action: JM to add Harrogate pathway to agenda when published. New Action: JM to meet with business manager in ophthalmology to discuss drafting HUTH pathway and work towards commissioning. September 2022 update – HUTH D&T are escalating internally via their escalation process. New action for HAPC To prepare SCF • Prescribing guidelines – Dienogest pathway JM to confirm prescribing arrangements with specialist team- JM contacted Mrs Allen about initial prescribing, awaiting reply. JM to ensure available in HUTH • Prescribing guidelines – Renal transplant medicines JM to update with alternative H2 receptor antagonist and review plan for renal repatriation. August 2022 update – JM invited to renal policy meeting to discuss renal repatriation and SCFs – add this as separate action to HAPC tracker. Transplant medication to upload to HERPC website September 2022 update – awaiting policy group meeting JM unable to meet with renal team, contact in future and update next meeting 	Ongoing	JM	11/22
			Ongoing		
			Ongoing New action for HAPC tracker: JM to prepare SCF	JM	3/23
				JM	11/22
			Ongoing		
				JM	11/22
			Ongoing		
2022.10.07	Traffic Light Status	September 2022- HUTH D&T: Gefaxipant- Proposed as RED- used on private prescriptions only for cough clinic- HUTH only (note on net formulary not NHS)	Update formulary/red list		

		Roxadustat- proposed as RED- approved in line with TA. NICE compliance raised and requested discussion at IMOC relating to if blueteq is required.			
2022.10.08	Feedback from Integrated Medicines Optimisation Committee	Discussions about decision making at APC level being delegated. Helpful to record number and date of TA on decisions. No extra cost for RED drugs	Noted		
2022.10.09	Work plans	a) Joint formulary alignment – JM updating b) Shared care frameworks- JM updated c) Guidelines	Ongoing for information only		
2022.10.10	Ratification of guidelines and SCFs	a) Inclisiran guideline - Adapted from the HERPC blue guidance; to provide primary care information on initiation and continuation of inclisiran. Approved b) Lipid guideline - This guidance covers multiple pathways including primary prevention pathway, secondary prevention pathway and statin intolerance pathway and targets for treatment. Approved c) Dementia SCF (Hull and ERY) - Updated to cover all 3 services who can initiate drugs for dementia (HFT, HUTH and CHCP). Approved	All approved JM/AK to upload onto website and remove HERPC/NLAPC guidance	JM/AK	11/22
2022.10.11	Ratification of joint formulary	Chapter 2- JM contacted cardiology for feedback via Humber cardiology lead and they agreed with chapter following a few minor queries. Formulary approved and to upload onto netformulary	To upload onto netformulary and remove HERPC chapter when complete	JM/LS/AK	1/23
2022.10.12	RTDC updates	a) July 2022 b) August 2022 All NICE guidance discussed and decisions made around approval. Recommendation for icosepent ethyl (TA805) which are waiting for an application and update triglycerides pathway. This TA is potentially above delegated financial responsibility	To recommend TA 805 to IMOC noting request for application and updated pathway	JM	11/22
2022.10.13	Minutes from subcommittees	a) Joint formulary subcommittee (Nil this month) b) Guideline subcommittee (Nil this month)	Attached for info only		
2022.10.14	Additional minutes for information	a) HUTH D&TC (August 2022) b) HFT DTG (nil this month) c) NLAG M&T (August 2022) d) NYY APC (August 2022)	Attached for info only		
2022.10.15	AOB	AK raised point that Posiconazole has not been placed on NLaG formulary but used as supportive treatment within haematology. To add to formulary so no delay in treatment.	AK to update formulary	AK	11/22

		KMC contacted by a specialist in Sheffield, patient is turning 19 and will require medication for narcolepsy (sodium oxybate), KMc to confirm with relevant finance in Hull place that previous agreement to fund for this patient remains.			
2022.10.16	Date of next meeting	2 nd November 13.00 – 15.00 Teams			